Intelligent Investor

Cynata Therapeutics Limited (ASX: CYP) - Announcements

Current share price for CYP : $0.235 0.01 (4.44%)

ASX company news and announcements for Cynata Therapeutics Limited (CYP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cynata Therapeutics Limited (CYP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cynata Therapeutics Limited (CYP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cynata Therapeutics Limited (CYP)

Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg
Gain/Loss
$42 Quarterly Activity Report & Appendix 4C 30 Apr 2024 8:54AM $0.210 $0.235 $0.210 risen by 11.90%
$42 Notification regarding unquoted securities - CYP 17 Apr 2024 1:36PM $0.200 $0.235 $0.210 risen by 17.50%
$42 DFU Clinical Trial Enrolment Complete 8 Apr 2024 8:58AM $0.195 $0.235 $0.210 risen by 20.51%
$42 EU Approval for Phase 2 CYP-001 Trial in GvHD 20 Mar 2024 8:55AM $0.170 $0.235 $0.210 risen by 38.24%
$42 Cynata Presenting at Advanced Therapies Congress 18 Mar 2024 8:52AM $0.170 $0.235 $0.210 risen by 38.24%
$42 First Patient Treated in Phase 2 GvHD Trial 5 Mar 2024 8:54AM $0.190 $0.235 $0.210 risen by 23.68%
$42 Cynata Appoints New Chief Business Officer 29 Feb 2024 9:19AM $0.210 $0.235 $0.210 risen by 11.90%
$42 Encouraging Initial Data from CYP-006TK DFU Trial 26 Feb 2024 9:01AM $0.200 $0.235 $0.210 risen by 17.50%
$42 Appendix 4D & Half-Year Financial Statements 23 Feb 2024 3:22PM $0.210 $0.235 $0.210 risen by 11.90%
$42 Quarterly Activity Report & Appendix 4C 30 Jan 2024 8:56AM $0.135 $0.235 $0.210 risen by 74.07%
$42 Notification regarding unquoted securities - CYP 16 Jan 2024 4:29PM $0.135 $0.235 $0.210 risen by 74.07%
$42 Initial Results in First 16 DFU Patients Expected in Q1 2024 28 Dec 2023 8:52AM $0.120 $0.235 $0.210 risen by 95.83%
$42 Recruitment Completed in Phase 3 OA Clinical Trial 13 Dec 2023 9:46AM $0.120 $0.235 $0.210 risen by 95.83%
$42 Phase 2 Trial of CYP-001 in aGvHD Approved in Turkey 7 Dec 2023 9:39AM $0.115 $0.235 $0.210 risen by 104.35%
$42 Appendix 3Y - Dr Kilian Kelly 23 Nov 2023 9:13AM $0.125 $0.235 $0.210 risen by 88%
$42 Appendix 3Ys x 5 20 Nov 2023 4:41PM $0.120 $0.235 $0.210 risen by 95.83%
$42 Notification regarding unquoted securities - CYP 20 Nov 2023 4:31PM $0.120 $0.235 $0.210 risen by 95.83%
$42 Notification of cessation of securities - CYP 14 Nov 2023 4:29PM $0.130 $0.235 $0.210 risen by 80.77%
$42 Cynata Receives $2.315m R&D Tax Incentive Refund 14 Nov 2023 8:55AM $0.130 $0.235 $0.210 risen by 80.77%
$42 Final Director's Interest Notice 13 Nov 2023 2:45PM $0.130 $0.235 $0.210 risen by 80.77%
$42 Results of AGM 13 Nov 2023 12:40PM $0.130 $0.235 $0.210 risen by 80.77%
$42 AGM Presentations 13 Nov 2023 8:32AM $0.135 $0.235 $0.210 risen by 74.07%
$42 Phase 3 SCUlpTOR Osteoarthritis Clinical Trial Progress 6 Nov 2023 9:14AM $0.135 $0.235 $0.210 risen by 74.07%
$42 First USA site initiated in aGvHD trial 2 Nov 2023 9:30AM $0.125 $0.235 $0.210 risen by 88%
$42 Quarterly Activity Report & Appendix 4C 26 Oct 2023 2:18PM $0.120 $0.235 $0.210 risen by 95.83%

1 - 25 of 566 results

Page 1 of 23

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.